JGC Holdings Corporation is pleased to announce that JGC Japan Corporation has been awarded a construction project for a new bioactive pharmaceutical ingredient (API) manufacturing facility by Chugai Pharmaceutical Co., Ltd. group member Chugai Pharma Manufacturing Co., Ltd.
The project calls for the engineering, procurement, and construction (EPC) for a facility to be built at the Utsunomiya Plant of Chugai Pharma Manufacturing in Utsunomiya City, Tochigi Prefecture. The lump-sum contract is for an undisclosed amount, with completion of construction scheduled for May 2026.
The market for biopharmaceuticals has been expanding rapidly in recent years as highly effective drugs that act on specific cells and tissues and have few side effects.
In this project, a new bio-API manufacturing building (UT3) which will be responsible for the manufacture of clinical development products from the middle to later-stage, including those for Phase 1 and 2 investigational drugs, as well as early-stage commercial products will be constructed. This will further strengthen the in-house supply foundation from clinical development to initial production, thereby contributing to the rapid launch of in-house products.
The plant improves production efficiency through the implementation of new continuous production functions by introducing perfusion culture in addition to the conventional batch-type production system, and also works on measures to reduce environmental impacts (CFC-free design and energy-saving design) promoted by the company, thus contributing to the realization of next-generation biopharmaceutical plants.
As a leading contractor in the pharmaceutical field in Japan, the JGC Group has engaged in the design and construction of numerous pharmaceutical plants for about half a century since the 1980s. In addition to this extensive experience and knowledge, we believe this latest order is the result of the positive evaluation of our execution performance in the construction project of an API synthesis facility for low and mid-molecular weight pharmaceuticals currently underway at the Fujieda plant of the company.
Biopharmaceuticals require a high level of engineering due to the complexity of their molecular structures. The Group will continue to respond to these increasingly sophisticated manufacturing technologies and diversifying customer needs with optimal solutions that leverage its knowledge and technologies based on its proven track record, thereby contributing to the development of the pharmaceuticals field and responding to the world’s medical needs.
Source: JGC Holdings Corporation
Add a Comment